CClinicalTrials.gg
CompletedNCT00247910Updated Sep 19, 2011

Behavioural Treatment of Hypertension

An interventional study of Hydrochlorothiazide in Hypertension, sponsored by University of British Columbia. Completed at 1 site in Canada. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-09-19.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

The objective of the study is to determine whether psychological therapy (self-help or individualized intense stress management) is different than a single drug treatment in terms of their effectiveness for lowering blood pressure.

02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • hypertension, ambulatory BP, office resting BP, hydrochlorothiazide, stress reduction, self-help, psychotherapy, efficacy
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

This study's enrollment of 150 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

University of British Columbia is the lead sponsor of 1,309 studies on the registry; 253 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • must be at least 19 years of age
  • subjects can be male or female
  • subjects must have an average resting blood pressure of >140 systolic pressure an/ or >90 diastolic pressure off anti-hypertensive medication

Exclusion criteria

Exclusion Criteria:

  • must not be on more than 2 blood pressure lowering drugs
  • must not have known or suspected of having secondary hypertension on initial examination
  • must not be pregnant or anticipating pregnancy during study period
  • must not have history of allergy, hypersensitivity or intolerance to diuretics
  • must not have medical condition that may result in an unacceptable risk of complications due to uncontrolled hypertension during time period of study
  • must not have average resting BP readings that exceed 190 systolic, or 115 diastolic, or have two consecutive readings of 180 systolic or 110 diastolic
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Interventions

  • DrugHydrochlorothiazide

    Not recorded in detailed description.

06

What researchers measure

Primary outcomes

  1. Day time ambulatory BP

    Time frame: See description

Secondary outcomes

  1. 24 hour ambulatory BP, and office resting BP

    Time frame: See description

07

Study locations

1 site
  • UBC Hospital
    Vancouver, British Columbia V6T 2B5, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00247910
Lead sponsor
University of British Columbia
Collaborators
Canadian Institutes of Health Research (CIHR)
First posted
Nov 2, 2005
Start date
Oct 2001
Primary completion
Jun 2006
Completion
Jun 2006
Last update
Sep 19, 2011

Study contacts

Wolfgang Linden, PhD
principal investigator · University of British Columbia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion